4.6 Review

Update in the Percutaneous Management of Coronary Chronic Total Occlusions

Journal

JACC-CARDIOVASCULAR INTERVENTIONS
Volume 11, Issue 7, Pages 615-625

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jcin.2017.10.052

Keywords

chronic total occlusion; percutaneous coronary intervention; stable coronary artery disease

Funding

  1. Asahi Intecc
  2. ACIST Medical Systems
  3. Gilead
  4. The Medicines Company
  5. Boston Scientific
  6. Merck
  7. Osprey
  8. Biosensors

Ask authors/readers for more resources

Percutaneous coronary intervention (PCI) for chronic total occlusions (CTOs) has been rapidly evolving during recent years. With improvement in equipment and techniques, high success rates can be achieved at experienced centers, although overall success rates remain low. Prospective, randomized-controlled data regarding optimal use and indications for CTO PCI remain limited. CTO PCI should be performed when the anticipated benefit exceeds the potential risk. New high-quality studies of the clinical outcomes and techniques of CTO PCI are needed, as is the expansion of expert centers and operators that can achieve excellent clinical outcomes in this challenging patient and lesion subgroup. In the current review the authors summarize the latest publications in CTO PCI and provide an overview of the current state of the field. (c) 2018 the American College of Cardiology Foundation. Published by Elsevier. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available